1.
Yang J, Shamji A, Matchacheep S, Schreiber SL. Identification of a small-molecule inhibitor of class Ia PI3Ks with cell-based screening. Chem Biol. 2007;14(4):371-7. doi:10.1016/j.chembiol.2007.02.004.
1.
Kubota H, Lim J, Depew KM, Schreiber SL. Pathway development and pilot library realization in diversity-oriented synthesis: exploring Ferrier and Pauson-Khand reactions on a glycal template. Chem Biol. 2002;9(2):265-76.
1.
Janouskova H, Tekle GE, Bellini E, et al. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nat Med. 2017;23(9):1046-1054. doi:10.1038/nm.4372.
1.
Fancy SPJ, Harrington EP, Yuen TJ, et al. Axin2 as regulatory and therapeutic target in newborn brain injury and remyelination. Nat Neurosci. 2011;14(8):1009-16. doi:10.1038/nn.2855.
1.
Serra V, Eichhorn PJA, García-García C, et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest. 2013;123(6):2551-63. doi:10.1172/JCI66343.
1.
Kim YK, Lee J-S, Bi X, et al. The binding of fluorophores to proteins depends on the cellular environment. Angew Chem Int Ed Engl. 2011;50(12):2761-3. doi:10.1002/anie.201007626.
1.
Buskirk AR, Landrigan A, Liu DR. Engineering a ligand-dependent RNA transcriptional activator. Chem Biol. 2004;11(8):1157-63. doi:10.1016/j.chembiol.2004.05.017.